Literature DB >> 69511

Kinetics of the inactivation of human and bovine trypsins and chymotrypsins by alpha1-proteinase inhibitor and of their reactivation by alpha2-macroglobulin.

M Aubry, J Bieth.   

Abstract

The time dependency of inactivation of human cationic trypsin and chymotrypsin II and of bovine trypsin and alpha-chymotrypsin by human serum has been investigated. Since the molar concentration of serum alpha1-proteinase inhibitor is much higher than that of other inhibitors, this time dependence could be used to calculate the rate constants kass for the association of alpha1-proteinase inhibitor with the four proteases. The association process was found to be second order, with kass ranging from 1 x10(4) s-1 (human trypsin) to 2.6 x 10(6) s-1 (bovine chymotrypsin). The human proteases react much more slowly with human alpha1-proteinase inhibitor than the bovine ones. But, whatever the species, chymotrypsin is inhibited more quickly than trypsin. Addition of alpha2-macroblobulin to the inactive complexes resulted in a time-dependent regeneration of enzymic activity due to the formation of alpha2-macroglobulin-protease complexes. The reactivation (i.e. dissociation) process was first order and extremely slow: the half-life of the alpha1-proteinase inhibitor-proteinase complexes ranged from 8 days (bovine chymotrypsin) to 9 months (human chymotrypsin). The human proteases formed the most stable complexes with alpha1-proteinase inhibitor. The pathological implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 69511     DOI: 10.1016/0009-8981(77)90070-5

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  3 in total

1.  Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients.

Authors:  B L Zuraw; J G Curd
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

2.  Studies on the interactions of human pancreatic elastase 2 with human alpha 1-proteinase inhibitor and alpha 1-antichymotrypsin.

Authors:  M Davril; A Laine; A Hayem
Journal:  Biochem J       Date:  1987-08-01       Impact factor: 3.857

Review 3.  Fibrinolytic Enzymes for Thrombolytic Therapy.

Authors:  Swaroop S Kumar; Abdulhameed Sabu
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.